🚀 VC round data is live in beta, check it out!
Altamira Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Altamira Therapeutics and similar public comparables like bioXXmed, Lidds, QUIA PHARMA, Lipigon Pharmaceuticals and more.
Altamira Therapeutics Overview
About Altamira Therapeutics
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy, viral infections, and inner ear disorders. Its product Bentrio, is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows for the delivery of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
Founded
2003
HQ
Employees
13
Website
Sectors
Financials (FY)
EV
$1M
Altamira Therapeutics Financials
Altamira Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($8M).
In the same fiscal year, Altamira Therapeutics generated ($8M) in EBITDA losses and had net loss of ($8M).
Revenue (LTM)
Altamira Therapeutics P&L
In the most recent fiscal year, Altamira Therapeutics reported revenue of — and EBITDA of ($8M).
Altamira Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($8M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Altamira Therapeutics Stock Performance
Altamira Therapeutics has current market cap of $343K, and enterprise value of $1M.
Market Cap Evolution
Altamira Therapeutics' stock price is $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1M | $343K | 0.0% | XXX | XXX | XXX | $-1.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAltamira Therapeutics Valuation Multiples
Altamira Therapeutics trades at (0.1x) EV/EBITDA.
Altamira Therapeutics Financial Valuation Multiples
As of April 19, 2026, Altamira Therapeutics has market cap of $343K and EV of $1M.
Equity research analysts estimate Altamira Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Altamira Therapeutics has a P/E ratio of (0.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $343K | XXX | $343K | XXX | XXX | XXX |
| EV (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.2x) | XXX | XXX | XXX |
| P/E | — | XXX | (0.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Altamira Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Altamira Therapeutics Margins & Growth Rates
Altamira Therapeutics' revenue in the last fiscal year grew by —.
Altamira Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Altamira Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Altamira Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Altamira Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| bioXXmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Lidds | XXX | XXX | XXX | XXX | XXX | XXX |
| QUIA PHARMA | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipigon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxurion | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Altamira Therapeutics M&A Activity
Altamira Therapeutics acquired XXX companies to date.
Last acquisition by Altamira Therapeutics was on XXXXXXXX, XXXXX. Altamira Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Altamira Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAltamira Therapeutics Investment Activity
Altamira Therapeutics invested in XXX companies to date.
Altamira Therapeutics made its latest investment on XXXXXXXX, XXXXX. Altamira Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Altamira Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Altamira Therapeutics
| When was Altamira Therapeutics founded? | Altamira Therapeutics was founded in 2003. |
| Where is Altamira Therapeutics headquartered? | Altamira Therapeutics is headquartered in United States. |
| How many employees does Altamira Therapeutics have? | As of today, Altamira Therapeutics has over 13 employees. |
| Is Altamira Therapeutics publicly listed? | Yes, Altamira Therapeutics is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Altamira Therapeutics? | Altamira Therapeutics trades under CYTOF ticker. |
| When did Altamira Therapeutics go public? | Altamira Therapeutics went public in 2014. |
| Who are competitors of Altamira Therapeutics? | Altamira Therapeutics main competitors are bioXXmed, Lidds, QUIA PHARMA, Lipigon Pharmaceuticals. |
| What is the current market cap of Altamira Therapeutics? | Altamira Therapeutics' current market cap is $343K. |
| Is Altamira Therapeutics profitable? | No, Altamira Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.